Skip to content
Pharma Observatory a Scientist.com platform

Organization (Industry)

JOHNSON & JOHNSON VISION CARE, INC.

ClinicalTrials.gov lists JOHNSON & JOHNSON VISION CARE, INC. as lead sponsor of 221 trials. It has 3 active development programs.

US Industry Manufacturer
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

22 0 2003 2027

Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

2026 is partial: 3 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 4 in 2026 and about 5 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (5 to 20), forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Logo Johnson & Johnson Services, Inc., via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.

This page covers JOHNSON & JOHNSON VISION CARE, INC.: 221 lead-sponsored trials and 3 legal-entity registrations. Part of KENVUE INC..

Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.

Get the JOHNSON & JOHNSON VISION CARE, INC. report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Disease areas (13)

Shown in this order: most trials first (counted at this company's own legal-entity record, not the consolidated group).

Disease areas
Disease area Trials
Myopia 46
Astigmatism 18
Presbyopia 10
Vision Disorders 5
Dry Eye Syndromes 5

Trials by start year as sponsor or collaborator (22)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Show the table of trials by start year as sponsor or collaborator
Trials by start year as sponsor or collaborator
Year Trials started
2026 (partial year) 3
2025 5
2024 6
2023 7
2022 15
2021 21
2020 11
2019 12
2018 22
2017 14

Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

Active development programs (3)

Shown in this order: max phase, then active trials.

Active development programs
Drug Disease area Max phase Trials
Investigational Lubricating Eye Drop in a Novelia® bottle Dry Eye Syndromes Phase 2 1
Blink® Tears eye Drops Dry Eye Syndromes Phase 2 1
Intervention Myopia Not reported 1

Sponsor delivery record (1)

Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.

Sponsor delivery record
Enrollment Timeline
47% hit target (n=55) 31% on time (n=54)

FDA inspection record (1)

FDA inspection record
Latest classification Inspections
NAI 3

FDA recalls (10)

Shown in this order: most recent first.

FDA recalls
Product Classification Initiated
ACUVUE¿ OASYS MAX 1-Day MULTIFOCAL Class II 2025-06-12
ACUVUE VITA soft (hydrophilic) contact lens (spherical) for daily wear. Base Curve 8.8, Refractive Power -1.50 Class II 2021-05-06
ACUVUE OASYS for ASTIGMATISM brand contact lenses, Base Curve 8.6 Refractive Power -1.00D, -1.25D x 100, 6 pack. Class II 2019-03-11
Johnson and Johnson Vision Care 1-Day ACUVUE MOIST Daily Wear, 8.5 Base Curve, -3.25 Power. Master Lot, containing 12 split lots, repackaged in 30 and 90-packs . Intended for daily disposable wear for the optical correction of refractive ametropia (myopia and hyperopia) in phakic or aphakic persons with non-diseased eyes who may have 1.00D or less of astigmatism. Class II 2018-07-23
ACUVUE OASYS for ASTIGMATISM Brand Contact Lenses. Lot no. B00NKM0G. Base Curve 8.6, Refractive Power -3.00D-1.25/90. Class II 2017-12-18

FDA import refusals (1)

FDA import refusals
Refused import lines Latest refusal
99 2026-08-10

Manufacturing and distribution sites (1)

Manufacturing and distribution sites
Facility Location Regulators Member organization
JOHNSON & JOHNSON VISION CARE, INC. Jacksonville, US FDA

Biomarker capability evidence (46)

Shown in this order: tier desc, then gene symbol.

Biomarker capability evidence
Gene Role Evidence
DGAT2L6 Trial sponsor Named in trial inclusion criteria
METTL5 Trial sponsor Named in trial inclusion criteria
GYPC Trial sponsor Named in trial exclusion criteria
GYPC Trial sponsor Named in trial exclusion criteria
GYPC Trial sponsor Named in trial exclusion criteria

Not on this page

Checked, with nothing recorded for this organization: companies grouped under this page, approved assets, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, climate targets, as filed, workforce and board diversity, as filed, organization relationships, and clia clinical laboratory certificates.

Counted at group level under Johnson & Johnson: journals published in, us granted patents, latest dated events, and biomarkers this organization publishes on.